Celyad - Model CYAD-101 - Allogeneic CAR T Candidate

CYAD-101 is an investigational, non-gene edited allogeneic (from healthy donor derived) CAR T candidate engineered to co-express the chimeric antigen receptor based on NKG2D, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed by a broad range of tumor cells and the novel inhibitory peptide TIM (TCR Inhibitory Molecule). The expression of TIM reduces signaling of the TCR complex by interfering with the CD3ζ component of the TCR complex. Celyad Oncology plans to initiate the KEYNOTE-B79 trial to evaluate CYAD-101 with Merck’s anti-PD­1 therapy, KEYTRUDA (pembrolizumab), in refractory mCRC patients with microsatellite stable / mismatch-repair proficient disease during the fourth quarter of 2021.